Overview

Dexmedetomidine on Tourniquet Induced -Systemic Effects

Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
0
Participant gender:
All
Summary
Eighty patients were randomly assigned to either control (CON) or dexmedetomidine (DEX) group. DEX group received a loading dose of 0.5 µg/ kg of intravenous dexmedetomidine over 10 minutes, followed by a continuous infusion of 0.5 µg/kg/h until completion of the surgery. CON group received the same calculated volume of normal saline. Pain outcomes, metabolic and coagulative changes after tourniquet application, and after tourniquet release were investigated.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wonkwang University Hospital
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- patients aged between 20 and 80 years, American Society of Anesthesiologists (ASA)
physical status class I-III, who were scheduled to undergo elective TKA

Exclusion Criteria:

- Patients with history of rheumatoid arthritis, diabetes mellitus, hepatic or renal
disease, allergy to drug being studied, heart block greater than first degree, left
ventricle ejection fraction < 55%, or chronic administration of anti-inflammatory
drugs, or opioids were excluded. Patients with tourniquet times of less than 60
minutes or longer than 150 minutes or with conversion to general anesthesia during
surgery